0001193125-23-130537.txt : 20230501 0001193125-23-130537.hdr.sgml : 20230501 20230501163056 ACCESSION NUMBER: 0001193125-23-130537 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230501 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230501 DATE AS OF CHANGE: 20230501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COMMUNITY HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0001108109 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 133893191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15925 FILM NUMBER: 23874210 BUSINESS ADDRESS: STREET 1: 4000 MERIDIAN BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 BUSINESS PHONE: 615-465-7000 MAIL ADDRESS: STREET 1: 4000 MERIDIAN BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 FORMER COMPANY: FORMER CONFORMED NAME: COMMUNITY HEALTH SYSTEMS INC/ DATE OF NAME CHANGE: 20000229 8-K 1 d485792d8k.htm FORM 8-K Form 8-K
COMMUNITY HEALTH SYSTEMS INC false 0001108109 0001108109 2023-05-01 2023-05-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 1, 2023

 

 

COMMUNITY HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-15925   13-3893191

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

4000 Meridian Boulevard

Franklin, Tennessee 37067

(Address of principal executive offices)

Registrant’s telephone number, including area code: (615) 465-7000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value   CYH   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


The information contained in this Current Report on Form 8-K (including the exhibits hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

 

ITEM 2.02

Results of Operations and Financial Condition

On May 1, 2023, Community Health Systems, Inc. (the “Company”) announced operating results for the first quarter ended March 31, 2023. A copy of the press release making this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.

 

ITEM 7.01

Regulation FD Disclosure

On May 1, 2023, the Company announced operating results for the first quarter ended March 31, 2023 in a press release attached as Exhibit 99.1 to this Current Report on Form 8-K which is incorporated by reference into this Item 7.01.

 

ITEM 9.01

Financial Statements and Exhibits

(d) Exhibits

The following exhibits are furnished herewith:

 

Exhibit

Number

  

Description

99.1    Community Health Systems, Inc. Press Release, dated May 1, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 1, 2023    

COMMUNITY HEALTH SYSTEMS, INC.

                        (Registrant)
    By:  

/s/ Tim L. Hingtgen

      Tim L. Hingtgen
      Chief Executive Officer and Director
      (principal executive officer)
    By:  

/s/ Kevin J. Hammons

      Kevin J. Hammons
      President and Chief Financial Officer
      (principal financial officer)
    By:  

/s/ Jason K. Johnson

      Jason K. Johnson
      Senior Vice President and Chief Accounting Officer
      (principal accounting officer)

 

3

EX-99.1 2 d485792dex991.htm EX-99.1 EX-99.1

Exhibit Number

99.1

 

LOGO

 

Investor Contact:   

Kevin Hammons

President and

Chief Financial Officer

(615) 465-7000

COMMUNITY HEALTH SYSTEMS, INC. ANNOUNCES FIRST QUARTER

ENDED MARCH 31, 2023 RESULTS

 

 

FRANKLIN, Tenn. (May 1, 2023) – Community Health Systems, Inc. (NYSE: CYH) (the “Company”) today announced financial and operating results for the three months ended March 31, 2023.

The following highlights the financial and operating results for the three months ended March 31, 2023.

 

   

Net operating revenues totaled $3.108 billion.

 

   

Net loss attributable to Community Health Systems, Inc. stockholders was $(51) million, or $(0.40) per share (diluted), compared to $(1) million, or $(0.01) per share (diluted), for the same period in 2022. Excluding the adjusting items as presented in the table in footnote (e) on page 12, net loss attributable to Community Health Systems, Inc. stockholders was $(0.43) per share (diluted), compared to net income of $0.14 per share (diluted) for the same period in 2022.

 

   

Adjusted EBITDA was $335 million.

 

   

Net cash provided by operating activities was $5 million for the three months ended March 31, 2023, compared to $101 million for the same period in 2022.

 

   

On a same-store basis, admissions increased 4.8 percent and adjusted admissions increased 9.4 percent, compared to the same period in 2022.

Commenting on the results, Tim L. Hingtgen, chief executive officer of Community Health Systems, Inc., said, “As the pandemic continues to subside and more patients return to healthcare settings, our healthcare teams delivered high quality services and our markets continued their progress, producing strong same-store inpatient and outpatient volume growth in the first quarter compared to the same period last year. Our emphasis on growth initiatives also helped generate sequential gains in same-store admissions, adjusted admissions, and surgeries compared to the fourth quarter of last year.”

Three Months Ended March 31, 2023

Net operating revenues for the three months ended March 31, 2023, totaled $3.108 billion, a 0.1 percent decrease compared to $3.111 billion for the same period in 2022. On a same-store basis, net operating revenues increased 1.7 percent for the three months ended March 31, 2023, compared to the same period in 2022. Net operating revenues for the three months ended March 31, 2023, reflect a 1.2 percent increase in admissions and a 5.8 percent increase in adjusted admissions, compared to the same period in 2022. On a same-store basis, admissions increased 4.8 percent and adjusted admissions increased 9.4 percent for the three months ended March 31, 2023, compared to the same period in 2022.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 2

May 1, 2023

 

Net loss attributable to Community Health Systems, Inc. stockholders was $(51) million, or $(0.40) per share (diluted), for the three months ended March 31, 2023, compared to $(1) million, or $(0.01) per share (diluted), for the same period in 2022. Excluding the adjusting items as presented in the table in footnote (e) on page 12, net loss attributable to Community Health Systems, Inc. stockholders was $(0.43) per share (diluted) for the three months ended March 31, 2023, compared to net income of $0.14 per share (diluted) for the same period in 2022. During the three months ended March 31, 2023, pandemic relief funds did not materially impact net loss attributable to Community Health Systems, Inc. stockholders. During the three months ended March 31, 2022, pandemic relief funds had a positive impact on net loss attributable to Community Health Systems, Inc. stockholders (both on a consolidated and adjusted basis) of approximately $35 million, or $0.27 on a per share (diluted) basis.

Adjusted EBITDA for the three months ended March 31, 2023, was $335 million compared to $409 million for the same period in 2022. During the three months ended March 31, 2023, pandemic relief funds did not materially impact Adjusted EBITDA. During the three months ended March 31, 2022, pandemic relief funds had a positive impact on Adjusted EBITDA of approximately $47 million.

The increase in net loss attributable to Community Health Systems, Inc. stockholders and decrease in Adjusted EBITDA for the three months ended March 31, 2023, compared to the same period in 2022, is primarily due to lower acuity and unfavorable changes in payor mix, increased salaries and benefits expense, increased rates for outsourced medical specialists and a reduction in pandemic relief funds recognized, partially offset by stronger volumes, higher reimbursement rates and reduced expense for contract labor.

Other

During 2023, through the date of this press release, the Company has completed the divestiture of two hospitals as more specifically described below. On January 1, 2023, the Company completed the divestiture of one hospital (in respect of which the Company received proceeds at a preliminary closing on December 31, 2022). On April 1, 2023, the Company completed the divestiture of one hospital (in respect of which the Company received proceeds at a preliminary closing on March 31, 2023). Financial and statistical data for 2023 and 2022 presented in this press release includes the operating results of divested or closed businesses for the periods prior to the consummation of the respective divestiture or closure. Same-store operating results exclude businesses divested in 2022 and the first quarter of 2023, businesses closed in 2022 and one de novo hospital that opened in 2022.

Information About Non-GAAP Financial Measures

This press release presents Adjusted EBITDA, a non-GAAP financial measure, which is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of equity interests in Macon Healthcare, LLC, expense related to government and other legal matters and related costs, income during the fourth quarter of 2021 associated with the settlement of litigation for the recovery of amounts of certain professional liability claims settled in 2020 covered by third-party insurance policies, expense related to employee termination benefits and other restructuring charges, the impact of a change in estimate to increase the professional liability claims accrual recorded during the fourth quarter of 2022 with respect to claims incurred in prior years related to divested locations and the gain on sale by HealthTrust Purchasing Group, L.P. (“HealthTrust”) of a majority interest in CoreTrust Holdings, LLC (“CoreTrust”) completed during the fourth quarter of 2022. For information regarding why the Company believes Adjusted EBITDA provides useful information to investors, and for a reconciliation of Adjusted EBITDA to net loss attributable to Community Health Systems, Inc. stockholders, see footnote (c) to the Financial Highlights, Financial Statements and Selected Operating Data below.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 3

May 1, 2023

 

Additionally, this press release presents adjusted net loss attributable to Community Health Systems, Inc. stockholders per share (diluted), a non-GAAP financial measure, to reflect the impact on net loss attributable to Community Health Systems, Inc. stockholders per share (diluted) from the selected items used in the calculation of Adjusted EBITDA. For information regarding why the Company believes this non-GAAP financial measure provides useful information to investors, and for a reconciliation of this non-GAAP financial measure to net loss attributable to Community Health Systems, Inc. stockholders per share (diluted), see footnote (e) to the Financial Highlights, Financial Statements and Selected Operating Data below.

The non-GAAP financial measures set forth above are not measurements of financial performance under U.S. GAAP, and should not be considered in isolation or as a substitute for any financial measure calculated in accordance with U.S. GAAP. Additionally, the calculation of these non-GAAP financial measures may not be comparable to similarly titled measures disclosed by other companies.

The Company’s annual earnings guidance for 2023, as provided in our press release issued on February 15, 2023, is reaffirmed. The 2023 guidance is based on the Company’s historical operating performance, current trends and other assumptions the Company believes are reasonable. Assumptions underlying the annual earnings guidance provided on February 15, 2023 are unchanged.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 44 distinct markets across 15 states. As of May 1, 2023, the Company’s subsidiaries own or lease 78 affiliated hospitals with approximately 13,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers.

The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.

Community Health Systems, Inc. will hold a conference call on Tuesday, May 2, 2023, at 10:00 a.m. Central, 11:00 a.m. Eastern, to review financial and operating results for the first quarter ended March 31, 2023. Investors will have the opportunity to listen to a live internet broadcast of the conference call by clicking on the Investor Relations link of the Company’s website at www.chs.net. For those who cannot listen to the live broadcast, a replay will be available shortly after the call and will continue to be available for approximately 30 days. Copies of this press release and conference call slide show, as well as the Company’s Current Report on Form 8-K (including this press release), will be available on the Company’s website at www.chs.net.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 4

May 1, 2023

 

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

Financial Highlights (a)(b)

(In millions, except per share amounts)

(Unaudited)

 

     Three Months Ended
March 31,
 
     2023     2022  

Net operating revenues

   $ 3,108     $ 3,111  

Net (loss) income (f)

     (20     30  

Net loss attributable to Community Health Systems, Inc. stockholders

     (51     (1

Adjusted EBITDA (c)

     335       409  

Net cash provided by operating activities

     5       101  

Loss per share attributable to Community Health Systems, Inc. stockholders:

    

Basic (f)

   $ (0.40   $ (0.01

Diluted (e), (f)

     (0.40     (0.01

Weighted-average number of shares outstanding (d):

    

Basic

     130       128  

Diluted

     130       128  

 

For footnotes, see pages 10, 11 and 12.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 5

May 1, 2023

 

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Loss (a)(b)

(In millions, except per share amounts)

(Unaudited)

 

     Three Months Ended March 31,  
     2023     2022  
     Amount     % of Net
Operating
Revenues
    Amount     % of Net
Operating
Revenues
 

Net operating revenues

   $ 3,108       100.0   $ 3,111       100.0

Operating costs and expenses:

        

Salaries and benefits

     1,365       43.9     1,325       42.6

Supplies

     507       16.3     499       16.0

Other operating expenses

     835       26.9     853       27.4

Lease cost and rent

     81       2.6     77       2.5

Pandemic relief funds

     —         —       (47     (1.5 )% 

Depreciation and amortization

     132       4.2     128       4.1

Impairment and (gain) loss on sale of businesses, net (f)

     (22     (0.7 )%      6       0.2
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs and expenses

     2,898       93.2     2,841       91.3
  

 

 

   

 

 

   

 

 

   

 

 

 

Income from operations (f)

     210       6.8     270       8.7

Interest expense, net

     207       6.7     217       7.0

Loss from early extinguishment of debt

     —         —       5       0.2

Equity in earnings of unconsolidated affiliates

     (3     (0.1 )%      (5     (0.2 )% 
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     6       0.2     53       1.7

Provision for income taxes

     26       0.8     23       0.7
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income (f)

     (20     (0.6 )%      30       1.0

Less: Net income attributable to noncontrolling interests

     31       1.0     31       1.0
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to Community Health Systems, Inc. stockholders

   $ (51     (1.6 )%    $ (1     0.0
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss per share attributable to Community Health Systems, Inc. stockholders:

        

Basic (f)

   $ (0.40     $ (0.01  
  

 

 

     

 

 

   

Diluted (e), (f)

   $ (0.40     $ (0.01  
  

 

 

     

 

 

   

Weighted-average number of shares outstanding (d):

        

Basic

     130         128    
  

 

 

     

 

 

   

Diluted

     130         128    
  

 

 

     

 

 

   

 

For footnotes, see pages 10, 11 and 12.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 6

May 1, 2023

 

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss

(In millions)

(Unaudited)

 

     Three Months Ended
March 31,
 
     2023     2022  

Net (loss) income

   $ (20   $ 30  

Other comprehensive income (loss), net of income taxes:

    

Net change in fair value of available-for-sale debt securities, net of tax

     3       (8
  

 

 

   

 

 

 

Other comprehensive income (loss)

     3       (8
  

 

 

   

 

 

 

Comprehensive (loss) income

     (17     22  

Less: Comprehensive income attributable to noncontrolling interests

     31       31  
  

 

 

   

 

 

 

Comprehensive loss attributable to Community Health Systems, Inc. stockholders

   $ (48   $ (9
  

 

 

   

 

 

 

 

For footnotes, see pages 10, 11 and 12.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 7

May 1, 2023

 

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

Selected Operating Data (a)

(Dollars in millions)

(Unaudited)

 

     Three Months Ended March 31,  
     Consolidated     Same-Store  
     2023     2022     % Change     2023     2022     % Change  

Number of hospitals (at end of period)

     79       83         78       78    

Licensed beds (at end of period)

     12,750       13,289         12,718       12,618    

Beds in service (at end of period)

     10,858       11,557         10,826       10,886    

Admissions

     109,624       108,367       1.2     108,923       103,918       4.8

Adjusted admissions

     245,883       232,315       5.8     244,040       222,984       9.4

Patient days

     507,925       551,245         505,699       532,724    

Average length of stay (days)

     4.6       5.1         4.6       5.1    

Occupancy rate (average beds in service)

     51.9     53.0       51.9     54.4  

Net operating revenues

   $ 3,108     $ 3,111       -0.1   $ 3,083     $ 3,032       1.7

Net inpatient revenues as a % of net operating revenues

     47.1     49.4       47.0     49.6  

Net outpatient revenues as a % of net operating revenues

     52.9     50.6       53.0     50.4  

Income from operations (f)

   $ 210     $ 270       -22.2      

Income from operations as a % of net operating revenues

     6.8     8.7        

Depreciation and amortization

   $ 132     $ 128          

Equity in earnings of unconsolidated affiliates

   $ (3   $ (5        

Net loss attributable to Community Health Systems, Inc. stockholders

   $ (51   $
(1

    -5,000      

Net loss attributable to Community Health Systems, Inc. stockholders as a % of net operating revenues

     -1.6     0.0        

Adjusted EBITDA (c)

   $ 335     $ 409       -18.1      

Adjusted EBITDA as a % of net operating revenues

     10.8     13.1        

Net cash provided by operating activities

   $ 5     $ 101       -95.0      

 

For footnotes, see pages 10, 11 and 12.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 8

May 1, 2023

 

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In millions, except share data)

(Unaudited)

 

                                                   
     March 31, 2023     December 31, 2022  

ASSETS

    

Current assets

    

Cash and cash equivalents

   $ 144     $ 118  

Patient accounts receivable

     2,043       2,040  

Supplies

     345       353  

Prepaid income taxes

     79       99  

Prepaid expenses and taxes

     276       237  

Other current assets

     227       235  
  

 

 

   

 

 

 

Total current assets

     3,114       3,082  
  

 

 

   

 

 

 

Property and equipment

     9,560       9,639  

Less accumulated depreciation and amortization

     (4,305     (4,274
  

 

 

   

 

 

 

Property and equipment, net

     5,255       5,365  
  

 

 

   

 

 

 

Goodwill

     4,051       4,166  
  

 

 

   

 

 

 

Deferred income taxes

     49       49  
  

 

 

   

 

 

 

Other asset, net

     2,154       2,007  
  

 

 

   

 

 

 

Total assets

   $ 14,623     $ 14,669  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

    

Current liabilities

    

Current maturities of long-term debt

   $ 39     $ 21  

Current operating lease liabilities

     138       148  

Accounts payable

     712       773  

Accrued liabilities:

    

Employee compensation

     596       637  

Accrued interest

     184       189  

Other

     463       418  
  

 

 

   

 

 

 

Total current liabilities

     2,132       2,186  
  

 

 

   

 

 

 

Long-term debt (g)

     11,696       11,614  
  

 

 

   

 

 

 

Deferred income taxes

     351       354  
  

 

 

   

 

 

 

Long-term operating lease liabilities

     588       605  
  

 

 

   

 

 

 

Other long-term liabilities

     647       644  
  

 

 

   

 

 

 

Total liabilities

     15,414       15,403  
  

 

 

   

 

 

 

Redeemable noncontrolling interests in equity of consolidated subsidiaries

     561       541  
  

 

 

   

 

 

 

STOCKHOLDERS DEFICIT

    

Community Health Systems, Inc. stockholders’ deficit:

    

Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued

     —         —    

Common stock, $.01 par value per share, 300,000,000 shares authorized; 136,749,427 shares issued and outstanding at March 31, 2023, and 134,703,717 shares issued and outstanding at December 31, 2022

     1       1  

Additional paid-in capital

     2,054       2,084  

Accumulated other comprehensive loss

     (18     (21

Accumulated deficit

     (3,482     (3,431
  

 

 

   

 

 

 

Total Community Health Systems, Inc. stockholders’ deficit

     (1,445     (1,367

Noncontrolling interests in equity of consolidated subsidiaries

     93       92  
  

 

 

   

 

 

 

Total stockholders deficit

     (1,352     (1,275
  

 

 

   

 

 

 

Total liabilities and stockholders deficit

   $ 14,623     $ 14,669  
  

 

 

   

 

 

 

 

For footnotes, see pages 10, 11 and 12.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 9

May 1, 2023

 

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In millions)

(Unaudited)

 

                                               
     Three Months Ended March 31,  
     2023     2022  

Cash flows from operating activities

    

Net (loss) income

   $ (20   $ 30  

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

    

Depreciation and amortization

     132       128  

Deferred income taxes

     7       22  

Stock-based compensation expense

     6       5  

Impairment and (gain) loss on sale of businesses, net (f)

     (22     6  

Loss from early extinguishment of debt

     —         5  

Other non-cash expenses, net

     42       45  

Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:

    

Patient accounts receivable

     (2     (17

Supplies, prepaid expenses and other current assets

     (50     (40

Accounts payable, accrued liabilities and income taxes

     (32     (23

Other

     (56     (60
  

 

 

   

 

 

 

Net cash provided by operating activities

     5       101  
  

 

 

   

 

 

 

Cash flows from investing activities

    

Acquisitions of facilities and other related businesses

     (8     (1

Purchases of property and equipment

     (122     (97

Proceeds from disposition of hospitals and other ancillary operations

     92       2  

Proceeds from sale of property and equipment

     5       —    

Purchases of available-for-sale debt securities and equity securities

     (26     (31

Proceeds from sales of available-for-sale debt securities and equity securities

     61       24  

Purchases of investments in unconsolidated affiliates

     (5     (4

Increase in other investments

     (16     (14
  

 

 

   

 

 

 

Net cash used in investing activities

     (19     (121
  

 

 

   

 

 

 

Cash flows from financing activities

    

Repurchase of restricted stock shares for payroll tax withholding requirements

     (4     (8

Deferred financing costs and other debt-related costs

     —         (73

Proceeds from noncontrolling investors in joint ventures

     2       1  

Redemption of noncontrolling investments in joint ventures

     (1     —    

Distributions to noncontrolling investors in joint ventures

     (44     (29

Other borrowings

     29       27  

Issuance of long-term debt

     —         1,535  

Proceeds from ABL Facility

     815       —    

Repayments of long-term indebtedness

     (757     (1,480
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     40       (27
  

 

 

   

 

 

 

Net change in cash and cash equivalents

     26       (47

Cash and cash equivalents at beginning of period

     118       507  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 144     $ 460  
  

 

 

   

 

 

 

 

For footnotes, see pages 10, 11 and 12.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 10

May 1, 2023

 

Footnotes to Financial Highlights, Financial Statements and Selected Operating Data

 

(a)

Both financial and statistical results include the operating results of divested or closed businesses for the periods prior to the consummation of the respective divestiture or closing. Same-store operating results and statistical information exclude businesses divested in 2022 and the first quarter of 2023, businesses closed in 2022 and one de novo hospital opened in 2022. There were no discontinued operations reported for 2023 and 2022.

 

(b)

The following table provides information needed to calculate loss per share, which is adjusted for income attributable to noncontrolling interests (in millions):

 

     Three Months Ended
March 31,
 
     2022      2021  

Net loss attributable to Community Health Systems,Inc. stockholders:

     

Net (loss) income

   $ (20    $ 30  

Less: Income attributable to noncontrolling interests, net of taxes

     31        31  
  

 

 

    

 

 

 

Net loss attributable to Community Health Systems, Inc. stockholders — basic and diluted

   $ (51    $ (1
  

 

 

    

 

 

 

 

(c)

EBITDA is a non-GAAP financial measure which consists of net income (loss) attributable to Community Health Systems, Inc. before interest, income taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of equity interests in Macon Healthcare, LLC, expense related to government and other legal matters and related costs, income during the fourth quarter of 2021 associated with the settlement of litigation for the recovery of amounts of certain professional liability claims settled in 2020 covered by third-party insurance policies, expense related to employee termination benefits and other restructuring charges, the impact of a change in estimate to increase the professional liability claims accrual recorded during the fourth quarter of 2022 with respect to claims incurred in prior years related to divested locations and the gain on sale by HealthTrust of a majority interest in CoreTrust completed during the fourth quarter of 2022. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company’s hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company’s executive management team and is one of the primary metrics used in connection with determining short-term cash incentive compensation and the achievement of vesting criteria with respect to performance-based equity awards. In addition, management utilizes Adjusted EBITDA in assessing the Company’s consolidated results of operations and operational performance and in comparing the Company’s results of operations between periods. The Company believes it is useful to provide investors and other users of the Company’s financial statements this performance measure to align with how management assesses the Company’s results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company’s asset-based loan facility (the “ABL Facility”) and the Company’s existing note indentures, which is a key component in the determination of the Company’s compliance with certain covenants under the ABL Facility and such note indentures (including the Company’s ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the ABL Facility (although Adjusted EBITDA does not include all of the adjustments described in the ABL Facility). Adjusted EBITDA includes the Adjusted EBITDA attributable to hospitals that were divested during the course of such year, but in each case solely to the extent relating to the period prior to the consummation of the applicable divestiture.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 11

May 1, 2023

 

Footnotes to Financial Highlights, Financial Statements and Selected Operating Data (Continued)

 

Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures disclosed by other companies.

The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements (in millions):

 

     Three Months Ended
March 31,
 
     2023      2022  

Net loss attributable to Community Health Systems, Inc. stockholders

   $ (51    $ (1

Adjustments:

     

Provision for income taxes

     26        23  

Depreciation and amortization

     132        128  

Net income attributable to noncontrolling interests

     31        31  

Interest expense, net

     207        217  

Loss from early extinguishment of debt

     —          5  

Impairment and (gain) loss on sale of businesses, net

     (22      6  

Expense from government and other legal matters and related costs

     10        —    

Expense related to employee termination benefits and other restructuring charges

     2        —    
  

 

 

    

 

 

 

Adjusted EBITDA

   $ 335      $ 409  
  

 

 

    

 

 

 

 

(d)

The following table sets forth components reconciling the basic weighted-average number of shares to the diluted weighted-average number of shares (in millions):

 

     Three Months Ended
March 31,
 
     2023      2022  

Weighted-average number of shares outstanding—basic

     130        128  

Add effect of dilutive securities:

     

Stock awards and options

     —          —    
  

 

 

    

 

 

 

Weighted-average number of shares outstanding—diluted

     130        128  
  

 

 

    

 

 

 

The Company generated a net loss attributable to Community Health Systems, Inc. stockholders for both the three months ended March 31, 2023 and 2022, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated net income, the effect of stock awards and options on the diluted shares calculation would have been an increase of 468,193 shares and 2,198,436 shares during the three months ended March 31, 2023 and 2022, respectively.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 12

May 1, 2023

 

Footnotes to Financial Highlights, Financial Statements and Selected Operating Data (Continued)

 

 

(e)

The following supplemental table reconciles net loss attributable to Community Health Systems, Inc. stockholders, as reported, on a per share (diluted) basis, to net (loss) income attributable to Community Health Systems, Inc. stockholders per share (diluted) with the adjustments described herein (total per share amounts may not add due to rounding). The Company believes that the presentation of non-GAAP adjusted net (loss) income attributable to Community Health Systems, Inc. stockholders per share (diluted) presents useful information to investors by highlighting the impact on net loss attributable to Community Health Systems, Inc. stockholders per share (diluted) of selected items used in calculating Adjusted EBITDA which may not reflect the Company’s underlying operating performance and assisting in comparing the Company’s results of operations between periods.

 

     Three Months Ended
March 31,
 
     2023      2022  

Net loss per share (diluted), as reported

   $ (0.40    $ (0.01

Adjustments:

     

Loss from early extinguishment of debt

     —          0.11  

Impairment and (gain) loss on sale of businesses, net

     (0.11      0.04  

Expense from government and other legal matters and related costs

     0.06        —    

Expense related to employee termination benefits and other restructuring charges

     0.01        —    
  

 

 

    

 

 

 

Net (loss) income per share (diluted), excluding adjustments

   $ (0.43    $ 0.14  
  

 

 

    

 

 

 

 

(f)

Both income from operations and net (loss) income included a net non-cash income of $22 million and expense of $6 million for the three months ended March 31, 2023 and 2022, respectively, primarily from gains on the sale of certain businesses during such periods and also impairment charges to reduce the value of certain long-lived assets at businesses the Company identified for closure, sale or sold. These impairment charges do not have an impact on the calculation of the Company’s financial covenants under the ABL Facility.

 

(g)

The maximum aggregate principal amount under the ABL Facility is $1.0 billion, subject to borrowing base capacity. At March 31, 2023, the Company had outstanding borrowings of $125 million and approximately $792 million of additional borrowing capacity (after taking into consideration $83 million of outstanding letters of credit) under the ABL Facility.

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 13

May 1, 2023

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this press release other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company’s expected results to differ materially from those expressed in this press release.

These factors include, among other things:

 

   

general economic and business conditions, both nationally and in the regions in which we operate, including the current negative macroeconomic conditions, ongoing inflationary pressures that have significantly increased and may continue to significantly increase our expenses, the current high interest rate environment, ongoing challenging labor market conditions and labor shortages, and supply chain shortages and disruptions, including the current and/or potential future adverse impact of such economic conditions and other factors on our net operating revenues (including our service mix, revenue mix, payor mix and/or patient volumes) and our ability to collect outstanding receivables, as well as the potential impact on us of financial and capital market instability and/or disruptions to the banking system due to bank failures and other factors, including any potential impact on our ability to access and or obtain the return of cash and cash equivalents, and/or our ability to access credit, liquidity and capital market sources on acceptable terms or at all;

 

   

the impact of current or future federal and state health reform initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Affordable Care Act”), and the potential for changes to the Affordable Care Act, its implementation or its interpretation (including through executive orders and court challenges);

 

   

the extent to and manner in which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through legislation, regulation or otherwise;

 

   

the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process;

 

   

risks associated with our substantial indebtedness, leverage and debt service obligations, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness, and our ability to remain in compliance with debt covenants;

 

   

demographic changes;

 

   

changes in, or the failure to comply with, federal, state or local laws or governmental regulations affecting our business;

 

   

potential adverse impact of known and unknown legal, regulatory and governmental proceedings and other loss contingencies, including governmental investigations and audits, and federal and state false claims act litigation;

 

   

our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers;

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 14

May 1, 2023

 

   

changes in, or the failure to comply with, contract terms with payors and changes in reimbursement policies or rates paid by federal or state healthcare programs or commercial payors;

 

   

any security breaches, cyber-attacks, loss of data, other cybersecurity threats or incidents, and any actual or perceived failures to comply with legal requirements governing the privacy and security of health information or other regulated, sensitive or confidential information, or legal requirements regarding data privacy or data protection, and the impact of the security breach announced by us on February 13, 2023, including legal, reputational, and financial risks associated with this security breach, existing and/or any future litigation associated with this security breach, any potential regulatory inquiries to which we may become subject in connection with this security breach, and the extent of remediation and other additional costs that may be incurred by us in connection with this security breach;

 

   

any potential impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets;

 

   

changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies;

 

   

the effects related to the implementation of the sequestration spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and the potential for future deficit reduction legislation;

 

   

increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles;

 

   

the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing;

 

   

the impact of competitive labor market conditions and the shortage of nurses, including in connection with our ability to hire and retain qualified nurses, physicians, other medical personnel and key management, and increased labor expenses as a result of such competitive labor market conditions, inflation and competition for such positions;

 

   

any failure to obtain medical supplies or pharmaceuticals at favorable prices;

 

   

liabilities and other claims asserted against us, including self-insured professional liability claims;

 

   

competition;

 

   

trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals or via telehealth;

 

   

changes in medical or other technology;

 

   

changes in U.S. GAAP;

 

   

the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures;

 

   

our ability to successfully make acquisitions or complete divestitures, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures;

 

   

the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities;

 

   

our ability to successfully integrate any acquired hospitals and/or outpatient facilities, or to recognize expected synergies from acquisitions;

 

   

the impact of severe weather conditions and climate change, as well as the timing and amount of insurance recoveries in relation to severe weather events;

 

   

our ability to obtain adequate levels of insurance, including cyber, general liability, professional liability, and directors and officers liability insurance;

 

   

timeliness of reimbursement payments received under government programs;

 

-MORE-


CYH Announces First Quarter 2023 Results

Page 15

May 1, 2023

 

   

effects related to pandemics, epidemics, or outbreaks of infectious diseases, including the coronavirus causing the disease known as COVID-19;

 

   

developments related to COVID-19, including, without limitation, related to the length and severity of the pandemic; and the spread of potentially more contagious and/or virulent forms of the virus, including variants of the virus for which currently available vaccines, treatments and tests may not be effective or authorized;

 

   

any failure to comply with our obligations under license or technology agreements;

 

   

challenging economic conditions in non-urban communities in which we operate;

 

   

the concentration of our revenue in a small number of states;

 

   

our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives;

 

   

any changes in or interpretations of income tax laws and regulations; and

 

   

the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2023 and other filings filed with the SEC.

The consolidated operating results for the three months ended March 31, 2023, are not necessarily indicative of the results that may be experienced for any future periods. The Company cautions that the reaffirmation of our guidance for calendar year 2023 (which guidance was originally included in our February 15, 2023 press release) as set forth herein is based on currently available information. The Company undertakes no obligation to revise or update any forward-looking statements (including such guidance), or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 

-END-

EX-101.SCH 3 cyh-20230501.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cyh-20230501_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cyh-20230501_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g485792g0428042125228.jpg GRAPHIC begin 644 g485792g0428042125228.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 01, 2023
Cover [Abstract]  
Entity Registrant Name COMMUNITY HEALTH SYSTEMS INC
Amendment Flag false
Entity Central Index Key 0001108109
Document Type 8-K
Document Period End Date May 01, 2023
Entity Incorporation State Country Code DE
Entity File Number 001-15925
Entity Tax Identification Number 13-3893191
Entity Address, Address Line One 4000 Meridian Boulevard
Entity Address, City or Town Franklin
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37067
City Area Code (615)
Local Phone Number 465-7000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value
Trading Symbol CYH
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 d485792d8k_htm.xml IDEA: XBRL DOCUMENT 0001108109 2023-05-01 2023-05-01 COMMUNITY HEALTH SYSTEMS INC false 0001108109 8-K 2023-05-01 DE 001-15925 13-3893191 4000 Meridian Boulevard Franklin TN 37067 (615) 465-7000 false false false false Common Stock, $0.01 par value CYH NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d485792d8k.htm 7 d485792d8k.htm cyh-20230501.xsd cyh-20230501_lab.xml cyh-20230501_pre.xml d485792dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d485792d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d485792d8k.htm" ] }, "labelLink": { "local": [ "cyh-20230501_lab.xml" ] }, "presentationLink": { "local": [ "cyh-20230501_pre.xml" ] }, "schema": { "local": [ "cyh-20230501.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cyh", "nsuri": "http://www.chs.net/20230501", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d485792d8k.htm", "contextRef": "duration_2023-05-01_to_2023-05-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d485792d8k.htm", "contextRef": "duration_2023-05-01_to_2023-05-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.chs.net//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-23-130537-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-130537-xbrl.zip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end